Hepatology Medical Journal Abstracts
Advert for Healthcare Professionals only
Prediction of early allograft dysfunction using serum phosphorus level in living donor liver transplantation
Transplant International
Jan 2013
Prediction of early allograft dysfunction using serum phosphorus level in living donor liver transplantation
Serum phosphorus is greatly affected by liver surgeries, but its change after liver transplantation has not yet been clarified. We investigated the predictive role of serum phosphorus for early allograft dysfunction (EAD) after living donor liver transplantation (LDLT). Perioperative factors, including serum phosphorus..Transcapsular arterial neovascularization of liver transplants increases the risk of intraoperative bleeding during retransplantation
Transplant International
Jan 2013
Transcapsular arterial neovascularization of liver transplants increases the risk of intraoperative bleeding during retransplantation
Arterial neovascularization of liver grafts can be a source of significant blood loss during retransplantation. This study evaluated the effect of transcapsular arterial neovascularization on intraoperative blood loss during retransplantation and long-term follow-up. Eleven consecutive patients with transcapsular..Fatty liver is a good indicator of subclinical atherosclerosis risk in obese children and adolescents regardless of liver enzyme elevation
Acta Paediatrica
Dec 2012
Fatty liver is a good indicator of subclinical atherosclerosis risk in obese children and adolescents regardless of liver enzyme elevation
Aim: To investigate the presence of association between nonalcoholic fatty liver disease (NAFLD) and subclinical atherosclerosis using carotid intima media thickness (c-IMT) in obese children and adolescents. Additionally, we wished to investigate the relationship between fatty liver and elevated liver enzymes...The impact of wait list body mass index changes on the outcome after liver transplantation
Transplant International
Dec 2012
The impact of wait list body mass index changes on the outcome after liver transplantation
Obesity is associated with poor health outcomes in the general population, but the evidence surrounding the effect of body mass index (BMI) on postliver transplantation survival is contradictory. The aim of this study was to assess the impact of wait list BMI and BMI changes on the outcomes after liver transplantation...Stage of change and motivation to healthier lifestyle in nonalcoholic fatty liver disease
Journal of Hepatology
Nov 2012
Stage of change and motivation to healthier lifestyle in nonalcoholic fatty liver disease
Backgrounds & aims: Healthy diet and physical activity are the treatment cornerstones of nonalcoholic fatty liver disease (NAFLD); their effectiveness is however limited by difficulties in implementing lifestyle changes. We aimed to determine the stage of change and associated psychological factors as a prerequisite to..Hepatitis B-core Antibody Positive Donors in Liver Transplantation and Their Impact on Graft Survival: Evidence From The Liver Match Cohort Study
Journal of Hepatology
Nov 2012
Hepatitis B-core Antibody Positive Donors in Liver Transplantation and Their Impact on Graft Survival: Evidence From The Liver Match Cohort Study
Background: The appropriate allocation of grafts from HBcAb positive donors in liver transplantation is crucial; yet a consensus is still lacking. Methods: We evaluated this issue within Liver Match; a prospective observational Italian study. Data from 1437 consecutive; first transplants performed in 2007-2009 using..Model for end-stage liver disease-sodium and survival benefit in liver transplantation
Transplant International
Nov 2012
Model for end-stage liver disease-sodium and survival benefit in liver transplantation
There are currently no studies calculating the survival benefit of liver transplantation (LT) according to model for end-stage liver disease-sodium (MELD-Na) and based on the competing risk (CR) method. We enrolled consecutive adult patients with chronic end-stage liver disease entering the waiting list (WL) for..Sixty- versus thirty-seconds papillary balloon dilation after sphincterotomy for the treatment of large bile duct stones: A randomized controlled trial
Digestive and Liver Disease
Nov 2012
Sixty- versus thirty-seconds papillary balloon dilation after sphincterotomy for the treatment of large bile duct stones: A randomized controlled trial
Background: Endoscopic biliary sphincterotomy followed by endoscopic papillary balloon dilation is a promising method for large stones. However, there are no data on the optimal duration of papillary balloon dilation after a biliary sphincterotomy. Aims: To compare the effectiveness and complications of the endoscopic..Impact of genetic SLC28 transporter and ITPA variants on ribavirin serum level, hemoglobin drop and therapeutic response in patients with HCV infection
Journal of Hepatology
Nov 2012
Impact of genetic SLC28 transporter and ITPA variants on ribavirin serum level, hemoglobin drop and therapeutic response in patients with HCV infection
Background & Aims: In the last decade pegylated interferon-α (Peg-INF-α) plus ribavirin (RBV) was the standard treatment of chronic hepatitis C for genotype 1, and it remains the standard for genotypes 2 and 3. Recent studies reported associations between RBV-induced anemia and genetic polymorphisms of concentrative..Liver carcinogenesis: Rodent models of hepatocarcinoma and cholangiocarcinoma
Digestive and Liver Disease
Nov 2012
Liver carcinogenesis: Rodent models of hepatocarcinoma and cholangiocarcinoma
Hepatocellular carcinoma and cholangiocarcinoma are primary liver cancers, both represent a growing challenge for clinicians due to their increasing morbidity and mortality. In the last few years a number of in vivo models of hepatocellular carcinoma and cholangiocarcinoma have been developed. The study of these models..Dual Oral Therapy with Daclatasvir and Asunaprevir for Patients with HCV Genotype 1b Infection and Limited Treatment Options
Journal of Hepatology
Nov 2012
Dual Oral Therapy with Daclatasvir and Asunaprevir for Patients with HCV Genotype 1b Infection and Limited Treatment Options
Background & Aims: Improved therapeutic options for chronic hepatitis C virus (HCV) infection are needed for patients who are poor candidates for treatment with current regimens due to anticipated intolerability or low likelihood of response. Methods: In this open-label, phase 2a study of Japanese patients with chronic..Sustained virologic response rates with telaprevir by response after 4 weeks of lead-in therapy in patients with prior treatment failure
Journal of Hepatology
Nov 2012
Sustained virologic response rates with telaprevir by response after 4 weeks of lead-in therapy in patients with prior treatment failure
Background & Aims: For hepatitis C virus (HCV)-infected patients who have not responded to previous peginterferon/ribavirin treatment, it is unclear whether subsequent direct-acting antiviral therapy outcomes are better predicted by prior treatment response or by on-treatment response to a peginterferon/ribavirin..Non-alcoholic steatohepatitis: The role of oxidized low-density lipoproteins
Journal of Hepatology
Nov 2012
Non-alcoholic steatohepatitis: The role of oxidized low-density lipoproteins
Non-alcoholic steatohepatitis (NASH) is hallmarked by lipid accumulation in the liver (steatosis) along with inflammation (hepatitis). The transition from simple steatosis towards NASH represents a key step in pathogenesis, as it will set the stage for further severe liver damage. Yet, the pathogenesis behind hepatic..Performance of rapid tests for detection of HBsAg and anti-HBsAb in a large cohort, France
Journal of Hepatology
Nov 2012
Performance of rapid tests for detection of HBsAg and anti-HBsAb in a large cohort, France
Background and Aims: The systematic use of rapid tests performed at points-of-care may facilitate hepatitis B virus (HBV) screening and substantially increase HBV infection awareness. The objective of this study was to evaluate the effectiveness of such tests for HBsAg and anti-HBsAb detection among individuals..Vitamin D status does not predict sustained virologic response or fibrosis stage in chronic hepatitis C genotype 1 infection
Journal of Hepatology
Nov 2012
Vitamin D status does not predict sustained virologic response or fibrosis stage in chronic hepatitis C genotype 1 infection
Background & Aims: The relationship between vitamin D status and response to antiviral therapy and liver histology in hepatitis C virus genotype 1 (HCV-1) infection remains unclear with studies to date yielding inconsistent results and failing to use reference assay methodology. We therefore analyzed pre-treatment..Sofosbuvir (GS-7977) plus peginterferon/ribavirin in treatment-naïve patients with HCV genotype 1: a randomized, 28-day, dose-ranging trial
Journal of Hepatology
Nov 2012
Sofosbuvir (GS-7977) plus peginterferon/ribavirin in treatment-naïve patients with HCV genotype 1: a randomized, 28-day, dose-ranging trial
Background and Aims: Sofosbuvir (formerly GS-7977) is a pyrimidine nucleotide analog inhibitor of the hepatitis C virus (HCV) NS5B polymerase. We assessed the safety, tolerability, antiviral activity, and pharmacokinetics of sofosbuvir plus pegylated-interferon (peg-IFN)/ribavirin (RBV) in a 28-day, dose-ranging trial..Efficacy and Safety of Boceprevir plus Peginterferon-Ribavirin in Patients with HCV G1 Infection and Advanced Fibrosis/Cirrhosis
Journal of Hepatology
Nov 2012
Efficacy and Safety of Boceprevir plus Peginterferon-Ribavirin in Patients with HCV G1 Infection and Advanced Fibrosis/Cirrhosis
Background and Aims: We assessed the safety and efficacy of boceprevir (BOC) plus peginterferon-ribavirin (PR) in patients with HCV-G1 infection and advanced fibrosis/cirrhosis (Metavir F3/F4). Methods: In two randomized controlled studies in previously untreated and previous treatment-failures, patients received a..Non-Invasive Diagnosis of Non-Alcoholic Fatty Liver Disease – A Critical Appraisal
Journal of Hepatology
Nov 2012
Non-Invasive Diagnosis of Non-Alcoholic Fatty Liver Disease – A Critical Appraisal
Non-alcoholic fatty liver disease (NAFLD) affects one in every three subjects in the occidental world. The vast majority will not progress, but a relevant minority will develop liver cirrhosis and its complications. The classical gold-standard for diagnosing and staging NAFLD and assessing fibrosis is liver biopsy..miR-133a mediates TGF-β-dependent de-repression of collagen-synthesis in hepatic stellate cells during liver fibrosis
Journal of Hepatology
Nov 2012
miR-133a mediates TGF-β-dependent de-repression of collagen-synthesis in hepatic stellate cells during liver fibrosis
Background & Aims: miRNAs are novel regulators of organ fibrosis. miR-133a plays a role in cardiac and muscle remodeling, but its function in the liver is unclear. We therefore aimed at evaluating a possible function of miR-133a in hepatofibrogenesis. Methods: miR-133a levels were measured in whole liver samples from..Mouse KLF11 regulates hepatic lipid metabolism
Journal of Hepatology
Nov 2012
Mouse KLF11 regulates hepatic lipid metabolism
Background & Aims: Missense mutations in human Krüppel-like factor 11 (KLF11) lead to the development of diabetes as a result of impaired insulin synthesis in the pancreas. However, the role of KLF11 in peripheral tissues is largely unknown. The objective of this study is to evaluate the role of KLF11 in the regulation..Comparison of resection and ablation for hepatocellular carcinoma: a cohort study based on a Japanese nationwide survey
Journal of Hepatology
Nov 2012
Comparison of resection and ablation for hepatocellular carcinoma: a cohort study based on a Japanese nationwide survey
Background & Aims: The treatment of choice for early or moderately advanced hepatocellular carcinoma (HCC) with good liver function remains controversial. We evaluated the therapeutic impacts of surgical resection (SR), percutaneous ethanol injection (PEI), and radiofrequency ablation (RFA) on long-term outcomes in..Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir
Journal of Hepatology
Nov 2012
Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir
Background and Aims: Daclatasvir and asunaprevir are NS5A- and NS3 protease-targeted antivirals currently under development for treatment of chronic hepatitis C virus infection. Clinical data on baseline and on-treatment correlates of drug resistance and response to these agents are currently limited. Methods:..Cardiac structure and function are altered in adults with non-alcoholic fatty liver disease
Journal of Hepatology
Nov 2012
Cardiac structure and function are altered in adults with non-alcoholic fatty liver disease
Background and Aims: Non-alcoholic fatty liver disease (NAFLD) is associated with a twofold greater risk of developing cardiovascular disease than those without. Despite this, little is known about the effect of NAFLD upon cardiac function, limiting our ability to identify therapeutic strategies. This study aimed to..The added value of quality of life (QoL) for prognoses of overall survival in patients with palliative hepatocellular carcinoma
Journal of Hepatology
Nov 2012
The added value of quality of life (QoL) for prognoses of overall survival in patients with palliative hepatocellular carcinoma
Background: Several prognostic classifications (PCs) have been developed for use in palliative care for patients with hepatocellular carcinoma (HCC). We recently suggested that CLIP combined with WHO PS had the greatest discriminative power. We evaluated the prognostic value of quality of life (QoL) data and whether..The impact of patient and tumour baseline characteristics on the overall survival of patients with advanced hepatocellular carcinoma treated with sorafenib
Digestive and Liver Disease
Nov 2012
The impact of patient and tumour baseline characteristics on the overall survival of patients with advanced hepatocellular carcinoma treated with sorafenib
Background: Impact of patient and tumour baseline characteristics on the overall survival is not well characterized in patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib. Aims/Methods: Univariate/multivariate analyses were conducted to identify retrospectively the impact of baseline..Infliximab as a rescue-treatment in difficult-to-treat autoimmune hepatitis
Journal of Hepatology
Nov 2012
Infliximab as a rescue-treatment in difficult-to-treat autoimmune hepatitis
Background: Autoimmune hepatitis is a chronic inflammatory liver disease that leads to liver cirrhosis and corresponding complications if left untreated. Current standard treatment with azathioprine and prednisolone induces remission in the vast majority of patients. However, for those patients not responding to..miR-122 Regulates Collagen Production via Targeting Hepatic Stellate Cells and Suppressing P4HA1 Expression
Journal of Hepatology
Nov 2012
miR-122 Regulates Collagen Production via Targeting Hepatic Stellate Cells and Suppressing P4HA1 Expression
Background & Aims: MicroRNAs (miRNAs) have been shown to be involved in many biological processes by affecting their target gene expression. miR-122 has been extensively studied in hepatocarcinogenesis. However, a role of miR-122 in liver fibrosis remains unknown. Methods: The mRNA expression levels of miR-122, prolyl..Risk factors of non-alcoholic fatty liver disease in patients with inflammatory bowel disease
Journal of Crohn's and Colitis
Nov 2012
Risk factors of non-alcoholic fatty liver disease in patients with inflammatory bowel disease
Background: Metabolic risk factors are associated with non-alcoholic fatty liver disease (NAFLD), but they are less frequent in inflammatory bowel disease (IBD). Aim: This study evaluates the frequency of NAFLD and its risk factors among IBD patients including anti-TNF-α therapy. Methods: IBD patients who underwent..Futility Rules for Telaprevir Combination Treatment for Patients with Hepatitis C Virus Infection
Clinical Gastroenterology and Hepatology
Nov 2012
Futility Rules for Telaprevir Combination Treatment for Patients with Hepatitis C Virus Infection
For patients treated with telaprevir, peginterferon, and ribavirin, futility rules have been developed to prevent needless drug exposure and minimize development of drug-resistant variants for patients who have little or no chance of achieving a sustained virologic response. We performed retrospective analyses of data..Beneficial effect of splenic artery ligation on bacterial translocation after major liver resection in rats
Digestive and Liver Disease
Nov 2012
Beneficial effect of splenic artery ligation on bacterial translocation after major liver resection in rats
Objective: In major liver resection, bacterial translocation appears to be an important mechanism in the pathogenesis of spontaneous infection. This study was designed to investigate the effects of splenic artery ligation on bacterial translocation after major liver resection. Materials and methods: Rats were divided..Improved Inflammatory Activity With Peginterferon Alfa-2b Maintenance Therapy in Non-cirrhotic Prior Nonresponders: a Randomized Study
Journal of Hepatology
Nov 2012
Improved Inflammatory Activity With Peginterferon Alfa-2b Maintenance Therapy in Non-cirrhotic Prior Nonresponders: a Randomized Study
Background and Aims: Therapeutic options for patients failing hepatitis C retreatment are limited. EPIC3 included a prospective trial assessing long-term peginterferon alfa-2b (PEG-IFN alfa-2b) maintenance therapy in patients with METAVIR fibrosis scores (MFS) of F2 or F3 who previously failed hepatitis C retreatment...Suspected Greater Celandine hepatotoxicity: liver-specific causality evaluation of published case reports from Europe
European Journal of Gastroenterology & Hepatology
Dec 2011
Suspected Greater Celandine hepatotoxicity: liver-specific causality evaluation of published case reports from Europe
Background and objectives: In 21 published case reports, the use of the herb Greater Celandine (GC) (Chelidonium majus L.) has been causally related to liver injury, but a variety of confounding variables were evident that might have offset causality. This study reanalyses causality levels in these cases with a..A dual role for hypoxia inducible factor-1α in the hepatitis C virus lifecycle and hepatoma migration
Journal of Hepatology
Dec 2011
A dual role for hypoxia inducible factor-1α in the hepatitis C virus lifecycle and hepatoma migration
Background and aims: Hepatitis C virus (HCV) causes progressive liver disease and is a major risk factor for the development of hepatocellular carcinoma (HCC). However, the role of infection in HCC pathogenesis is poorly understood. We investigated the effect(s) of HCV infection and viral glycoprotein expression on..Short Course Adjuvant Terlipressin in Acute Variceal Bleed: A Randomized Double Blind Dummy Controlled Trial
Journal of Hepatology
Dec 2011
Short Course Adjuvant Terlipressin in Acute Variceal Bleed: A Randomized Double Blind Dummy Controlled Trial
Background & aims: Terlipressin is recommended for 3-5 days as adjuvant to Endoscopic Variceal Band Ligation (EVBL) in esophageal variceal bleed (EVB). We assessed if Terlipressin for shorter duration can be given in patients with EVB. Methods: All eligible EVB patients received 24 hours of open label Terlipressin at..End-stage liver disease candidates at the highest model for end-stage liver disease scores have higher wait-list mortality than status-1A candidates
Hepatology
Nov 2011
End-stage liver disease candidates at the highest model for end-stage liver disease scores have higher wait-list mortality than status-1A candidates
Candidates with fulminant hepatic failure (Status-1A) receive the highest priority for liver transplantation (LT) in the United States. However, no studies have compared wait-list mortality risk among end-stage liver disease (ESLD) candidates with high Model for End-Stage Liver Disease (MELD) scores to those listed as..Early changes in interferon signaling define natural killer cell response and refractoriness to interferon-based therapy of hepatitis C patients
Hepatology
Nov 2011
Early changes in interferon signaling define natural killer cell response and refractoriness to interferon-based therapy of hepatitis C patients
Natural killer (NK) cells exhibit a polarized phenotype with increased cytotoxicity and decreased interferon gamma (IFN-γ) production in chronic hepatitis C virus (HCV) infection. Here, we asked whether this is caused by type I interferon (IFN)-induced expression and phosphorylation levels of signal transducer and..Indeterminate 1-2-cm nodules found on hepatocellular carcinoma surveillance: Biopsy for all, some, or none?
Hepatology
Nov 2011
Indeterminate 1-2-cm nodules found on hepatocellular carcinoma surveillance: Biopsy for all, some, or none?
In the latest hepatocellular carcinoma (HCC) management guidelines by the American Association for the Study of Liver Diseases, biopsy is advocated for all nodules deemed indeterminate after imaging work-up by contrast-enhanced scans. However, the latest guidelines' imaging work-up algorithm has been shown to improve..Expression of HIWI in Human Hepatocellular Carcinoma
Cell Biochemistry and Biophysics
Sep 2011
Expression of HIWI in Human Hepatocellular Carcinoma
In this study, the investigation of the expression of HIWI and its protein in hepatocellular carcinoma (HCC) was performed, and the relationships between HIWI expression and the location of HCC metastases were analyzed. Sets of fresh HCC and matched adjacent normal hepatic tissue and paraffin-embedded tissue slides..The potential use of 2-[18F]fluoro-2-deoxy-D-galactose as a PET/CT tracer for detection of hepatocellular carcinoma
European Journal of Nuclear Medicine and Molecular Imaging
Sep 2011
The potential use of 2-[18F]fluoro-2-deoxy-D-galactose as a PET/CT tracer for detection of hepatocellular carcinoma
Purpose: The aim of the study was to evaluate the feasibility of using the hepatocyte-specific positron emission tomography (PET) tracer 2-[18F]fluoro-2-deoxy-D-galactose (FDGal) as a tracer for hepatocellular carcinoma (HCC). Methods: In addition to standard clinical investigations, 39 patients with known HCC or..Acute hepatitis C in Brazil: Results of a national survey
Journal of Medical Virology
Aug 2011
Acute hepatitis C in Brazil: Results of a national survey
The incidence of acute hepatitis C has decreased in the world. However, new cases are still reported. The objective of this study was to obtain data of acute hepatitis C in Brazil and to identify risk factors of transmission, diagnostic criteria, clinical presentation, evolution, and treatment. A questionnaire was sent..
Advert for Healthcare Professionals only